The Impact of Pre-exposure Prophylaxis for Human Immunodeficiency Virus on Gonorrhea Prevalence

被引:3
|
作者
Pharaon, Joe [1 ]
Bauch, Chris T. [1 ]
机构
[1] Univ Waterloo, Dept Appl Math, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada
基金
加拿大创新基金会; 加拿大自然科学与工程研究理事会;
关键词
Mathematical model; HIV; Gonorrhea; Prophylaxis; Infectious disease epidemiology; Compartmental model; HIV-INFECTION; SAN-FRANCISCO; TRANSMISSION; MODEL; MEN; PREVENTION; DYNAMICS; SPREAD; SEX; MSM;
D O I
10.1007/s11538-020-00762-7
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Pre-exposure prophylaxis (PrEP) has been shown to be highly effective in reducing the risk of HIV infection in gay and bisexual men who have sex with men (GbMSM). However, PrEP does not protect against other sexually transmitted infections (STIs). In some populations, PrEP has also led to riskier behavior such as reduced condom usage, with the result that the prevalence of bacterial STIs like gonorrhea has increased. Here, we develop a compartmental model of the transmission of HIV and gonorrhea and the impacts of PrEP, condom usage, STI testing frequency and potential changes in sexual risk behavior stemming from the introduction of PrEP in a population of GbMSM. We find that introducing PrEP causes an increase in gonorrhea prevalence for a wide range of parameter values, including at the currently recommended frequency of STI testing once every three months for individuals on PrEP. Moreover, the model predicts that a higher STI testing frequency alone is not enough to prevent a rise in gonorrhea prevalence, unless the testing frequency is increased to impractical levels. However, testing every 2 months in combination with a 10-25 % reduction in risky behavior by individuals on PrEP would maintain gonorrhea prevalence at pre-PrEP levels. The results emphasize that programs making PrEP more available should be accompanied by efforts to support condom usage and frequent STI testing, in order to avoid an increase in the prevalence of gonorrhea and other bacterial STIs.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Rectal Microbiome Alterations Associated With Oral Human Immunodeficiency Virus Pre-Exposure Prophylaxis
    Fulcher, Jennifer A.
    Li, Fan
    Cook, Ryan R.
    Zabih, Sara
    Louie, Alexander
    Okochi, Hideaki
    Tobin, Nicole H.
    Gandhi, Monica
    Shoptaw, Steven
    Gorbach, Pamina M.
    Aldrovandi, Grace M.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (11):
  • [22] Linking emergency department patients at risk for human immunodeficiency virus to pre-exposure prophylaxis
    Mahal, Jacqueline
    Deccy, Stephanie
    Seu, Rie
    [J]. AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2022, 54 : 87 - 90
  • [23] Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention
    Glaubius, Robert L.
    Parikh, Urvi M.
    Hood, Greg
    Penrose, Kerri J.
    Bendavid, Eran
    Mellors, John W.
    Abbas, Ume L.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2016, 3 (03):
  • [24] Human Immunodeficiency Virus Pre-Exposure Prophylaxis: The Next Wave in Emergency Department-Based Human Immunodeficiency Virus Prevention
    Haukoos, Jason
    Faryar, Kiran
    Rowan, Sarah
    [J]. ANNALS OF EMERGENCY MEDICINE, 2023, 81 (04) : 482 - 484
  • [25] Incidence of Hepatitis C Virus Infections Among Users of Human Immunodeficiency Virus Pre-exposure Prophylaxis
    Tabatabavakili, Sahar
    Aleyadeh, Wesam
    Cerrocchi, Orlando
    Janssen, Harry L. A.
    Hansen, Bettina E.
    Bogoch, Isaac I.
    Feld, Jordan J.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (03) : 674 - 681
  • [26] Usability and Utility of Human Immunodeficiency Virus Pre-exposure Prophylaxis Clinical Decision Support to Increase Knowledge and Pre-exposure Prophylaxis Initiations among Pediatric Providers
    Chan, Carrie T. T.
    Carlson, Jennifer
    Lee, Tzielan
    Vo, Megen
    Nasr, Annette
    Hart-Cooper, Geoffrey
    [J]. APPLIED CLINICAL INFORMATICS, 2022, 13 (05): : 1141 - 1150
  • [27] Community pharmacists' acceptance of prescribing for pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV)
    Booker, Connor
    Murphy, Andrea L.
    Isenor, Jennifer E. E.
    Ramsey, Tasha D. D.
    Smith, Alesha J. J.
    Bishop, Andrea
    Kelly, Deborah V. V.
    Woodill, Lisa
    Richard, Greg
    Wilby, Kyle John
    [J]. CANADIAN PHARMACISTS JOURNAL, 2023, 156 (03) : 137 - 149
  • [28] Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012-2017
    Huang, Ya-Lin A.
    Tao, Guoyu
    Smith, Dawn K.
    Hoover, Karen W.
    [J]. CLINICAL INFECTIOUS DISEASES, 2021, 72 (03) : 379 - 385
  • [29] Human immunodeficiency virus and pre-exposure prophylaxis. Relevance for other sexually transmitted infections
    Fregoso, Jose Garcia
    Krekels, Morgan
    Mordhorst, Isabel
    Potthoff, Anja
    [J]. COLOPROCTOLOGY, 2024,
  • [30] A survey of South Carolina pharmacists' readiness to prescribe human immunodeficiency virus pre-exposure prophylaxis
    Burns, Charles M.
    Endres, Kyle
    Derrick, Caroline
    Cooper, Alexandra
    Fabel, Patricia
    Okeke, Nwora Lance
    Ahuja, Divya
    Corneli, Amy
    McKellar, Mehri S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2023, 6 (04): : 329 - 338